Inoserp^TM PAN-AFRICA is composed of equine derived antibodies or immunoglobulin fragments F(ab’)₂, which have been raised against the venoms of medically important species of the sub-Saharan region.

A recent cross-neutralization study has shown that the antivenom actually covers 6 additional species through cross-neutralization: Atractaspis irregularis, Cerastes cerastes, Dispolidus typus, Naja anchieta, Naja annulifera, Naja mossambica. Overall, with 24 species, Inoserp^TM PAN-AFRICA provides the largest coverage of medically important species in sub-Saharan Africa⁽¹⁾.

• Inosan Biopharma antivenoms are polyvalent and cover most species that are medically important for the relevant region. Venoms used for the immunization process come from species representative of the regions the antivenoms are intended for.
• Inosan antivenoms are made of highly specific F(ab’)₂⁽²⁾, meaning that there is a high proportion of effective F(ab’)₂ capable to specifically bind to the toxic components of the venoms and neutralize them. Thanks to its high specificity, Inosan antivenoms can include more species in one vial with less proteins.
• Inosan Biopharma antivenoms are highly purified level with F(ab’)₂ level reaching 95%⁽²⁾. They have a low protein level (<10%, no more than 100 mg of protein per mL in the resuspended product) and are preservatives free.

The rate of amputation and death has been shown to be very low following the use of Inoserp^TM PAN-AFRICA. In a recent independent review of the available clinical data, Inoserp^TM PAN-AFRICA appears in the short-list of polyvalent antivenoms available in sub-Saharan Africa with the most favorable benefit/risk ratio⁽⁴⁾.

According to the clinical studies performed, adverse events have been reported in less than 10% of patients⁽⁵⁾. They may include sweating, nausea, rashes, modest decrease in blood pressure, anaphylactoid reaction (allergic type) associated with facial erythema and cough. The risk of an anaphylactic shock cannot be excluded but remains very rare. Similar reactions to serum sickness may appear after around 6 days of the onset of the treatment. The clinical signs are fever, pruritus, erythema or urticaria, adenopathy, and arthralgia. However, this type of reactions is observed in less than 1% of the patients.

Inoserp^TM PAN-AFRICA should be administered intravenously through slow direct injection of infusion. It is recommended to evaluate the patient every 2 hours after the initial administration and to renew administration (2 vials) as long as symptoms persist or are getting worse. A larger number of vials might be administered depending on the severity or the type of envenomation such as neurotoxic bites.

Due to the fatal risk associated with envenomation, Inosan Biopharma antivenoms may be dispensed in the specific population of allergic patients to equine origin proteins, provided that treatment for anaphylactic shock can be implemented immediately<.

Envenomation in children generally leads to more severe symptoms and a higher rate of lethality and sequelae. This is due to their small body weight and volume that lead to a lower dilution of venom. Available clinical data show that the safety and efficacy in the pediatric population is not different from the adults⁽⁴⁾.

Inosan Biopharma antivenoms are lyophilized, this makes the management of the antivenom very convenient and inexpensive compared to liquid presentations, particularly in tropical regions.

Inosan Biopharma maintains GMP certification at all times from COFEPRIS, the Mexican agency, recognized by the WHO, for the qualification of manufacturers of vaccines and biological products. In addition, Inosan follows the guidelines for the manufacturing of antivenom products established by the WHO.